Scarica l'app Stockscreener
36.34
0.42%
0.16
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Royalty Pharma Plc Borsa (RPRX) Ultime notizie
Why retail investors pile into Royalty Pharma plc stock2025 Historical Comparison & Free Growth Oriented Trading Recommendations - newser.com
What’s the recovery path for long term holders of Royalty Pharma plcMarket Risk Analysis & Safe Capital Growth Trade Ideas - newser.com
Morningstar Investment Management LLC Acquires Shares of 8,307 Royalty Pharma PLC $RPRX - MarketBeat
What indicators show strength in Royalty Pharma plcJuly 2025 Movers & Breakout Confirmation Trade Signals - newser.com
Callan Family Office LLC Buys Shares of 16,418 Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma (RPRX) Valuation: Is There More Upside After This Year’s 40% Rally? - Yahoo Finance
Royalty pharma projects 6-12% growth in 2025 portfolio receipts with $2B share buyback plan - MSN
Royalty Pharma plc (RPRX) Stock Analysis: Unveiling a 23.59% Upside Potential in the Biotech Royalty Space - DirectorsTalk Interviews
Is this a good reentry point in Royalty Pharma plcQuarterly Investment Review & AI Forecasted Stock Moves - newser.com
Royalty Pharma PLC $RPRX Shares Sold by Board of the Pension Protection Fund - MarketBeat
Inspire Investing LLC Buys 22,436 Shares of Royalty Pharma PLC $RPRX - MarketBeat
What candlestick patterns are forming on Royalty Pharma plcJuly 2025 Setups & Risk Managed Investment Signals - newser.com
Royalty Pharma to buy royalty interest in Amgen’s Imdelltra for up to $950M - MSN
KLP Kapitalforvaltning AS Increases Position in Royalty Pharma PLC $RPRX - MarketBeat
Belpointe Asset Management LLC Purchases New Position in Royalty Pharma PLC $RPRX - MarketBeat
Why Royalty Pharma plc (RPD) stock could rally stronglyJuly 2025 Sector Moves & Risk Controlled Stock Alerts - newser.com
Royalty Pharma To Announce Third Quarter 2025 Financial Results On November 5, 2025 - TradingView
Royalty Pharma to Announce Third Quarter 2025 Financial Results on November 5, 2025 - The Manila Times
Q3 2025 Results Nov 5: Royalty Pharma to Report Results and Host Call/Webcast at 8:00 a.m. ET - Stock Titan
Custom watchlist performance reports with Royalty Pharma plcPortfolio Profit Report & Safe Capital Growth Tips - newser.com
Royalty Pharma (NASDAQ:RPRX) Raised to Buy (B-) at Weiss Ratings - MarketBeat
Is Royalty Pharma plc stock a smart buy before Fed meeting2025 Top Gainers & AI Enhanced Execution Alerts - newser.com
Will Royalty Pharma (RPRX) Beat Estimates Again in Its Next Earnings Report? - sharewise.com
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises - Yahoo Finance
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar - sharewise.com
Why Royalty Pharma plc stock is a must watch in 2025Weekly Trading Summary & AI Optimized Trade Strategies - newser.com
Understanding Royalty Pharma plc’s price movementMarket Growth Review & Accurate Technical Buy Alerts - newser.com
Royalty Pharma (RPRX) Stock Analysis: Unlocking a 23.72% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
A Look at Royalty Pharma’s (RPRX) Valuation Following Imdelltra Royalty Acquisition and Board Enhancement - Sahm
Will Royalty Pharma plc stock see PE expansion2025 Analyst Calls & AI Driven Price Predictions - newser.com
Royalty Pharma collaborates with Biogen for R&D funding - MSN
Royalty Pharma PLC $RPRX Position Increased by Robeco Institutional Asset Management B.V. - MarketBeat
Royalty Pharma PLC (NASDAQ:RPRX) Given Average Rating of "Buy" by Analysts - MarketBeat
11% Of This Royalty Pharma Insider's Holdings Were Sold - 富途牛牛
Will Royalty Pharma's (RPRX) Governance Shift Sharpen Its Edge in Life Sciences Investment? - simplywall.st
The Goldman Sachs Group Initiates Coverage on Royalty Pharma (NASDAQ:RPRX) - MarketBeat
The Best Biotech Stocks to Buy - Morningstar
Goldman Sachs initiates Royalty Pharma stock with Buy rating, $42 target - Investing.com Nigeria
Royalty Pharma : Q3 2025 Pre-Quarterly Results Communication - MarketScreener
Goldman Sachs Initiates Coverage of Royalty Pharma (RPRX) with Buy Recommendation - Nasdaq
Royalty Pharma plc Stock Analysis and ForecastPrice Action Analysis & High Profit Investment Ideas - earlytimes.in
4.86%
0.08%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):